Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887276 | 0.85 | MAPT (0.48) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL11369493 | 0.81 | GAPDH (0.51) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL14539204 | 0.78 | KCNH2 (0.57) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL8532102 | 0.78 | NQO1 (0.50) | ALDH1A1MEN1KMT2AHSD17B10NPC1 | |
| SCHEMBL984344 | 0.77 | MAOB (0.62) | ALDH1A1MAPTNPC1RAB9AMAOB | |
| SCHEMBL15067112 | 0.75 | NQO1 (0.48) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL17536735 | 0.75 | MAPT (0.39) | ALDH1A1MAPTKMT2AHSD17B10RAB9A | |
| SCHEMBL22208398 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL5907505 | 0.74 | MAOB (0.42) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL4009384 | 0.74 | MAP2K4 (0.46) | ALDH1A1MAPTKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| US-20050026903-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | ALDH1A1 1572/4885MAPT 2577/4885MEN1 1705/4885 |
| US-20050026903-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GLP1R | ALDH1A1 1501/4885MAPT 4745/4885MEN1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.